阿联酋启动全国范围内解决阿片类药物相关索赔

2026-01-30 00:23

Amneal Pharmaceuticals (AMRX) disclosed that its previously announced agreement to settle a majority of opioid-related claims against the company will take effect on Thursday, allowing claimants to receive up to $267M in cash and overdose treatments.
Under the Nationwide Opioids Settlement Agreement, the participating states and other jurisdictions can receive $88.5M in cash and up to $177.4M worth of opioid overdose therapy naloxone nasal spray.
The ten-year agreement also permits litigants to receive 25% of the naloxone nasal spray’s value as cash payments (subject to a maximum of $44.4M) instead of the product during the last four years of the decade-long payment term.
Based on the latter clause, the total cash payments due from the company can reach up to $132.9M under the agreement, Amneal (AMRX) said in a regulatory filing on Wednesday.

More on Amneal Pharmaceuticals